<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00296179</url>
  </required_header>
  <id_info>
    <org_study_id>PM_L_0166</org_study_id>
    <nct_id>NCT00296179</nct_id>
  </id_info>
  <brief_title>Ambien CR For Treatment Of Insomnia Associated With Depression When Used Concomitantly With Lexapro</brief_title>
  <official_title>Comparison of Zolpidem Tartrate Extended-Release vs. Placebo in Treatment of Insomnia Associated With Newly Diagnosed Major Depressive Disorder(MDD) or Untreated MDD Relapse, When Used Concomitantly With Escitalopram</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      To demonstrate overall improvement of insomnia in subjects treated with zolpidem tartrate
      extended-release (Ambien CR) and escitalopram (Lexapro) vs. subjects treated with placebo and
      escitalopram at 2 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Patient-reported TST</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in relapse rates in patients receiving placebo and patients receiving zolpidem MR during 4 month follow-up period</measure>
  </secondary_outcome>
  <enrollment>372</enrollment>
  <condition>Insomnia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zolpidem tartrate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        MAJOR INCLUSION CRITERIA:

          1. Must experience sleep disturbances at least 3 nights/week, based on historical data

          2. Must meet the diagnostic requirements for Major Depressive Disorder

          3. Must have QIDS-SR16 score between 6 and 15

          4. Must be either newly diagnosed or show symptoms of relapse/recurrence of depression
             while not on medication

          5. Age 21-64, inclusive

          6. Women must use a medically acceptable form of contraception (steroidal contraceptive,
             double-barrier, or intra-uterine device) during the entire study period, or: be
             surgically sterilized, post-menopausal, agree to use double-barrier contraception
             throughout the study period, or must have a negative urine pregnancy test prior to
             randomization.

          7. Subject must be stabilized on all ongoing long-term medication therapy for at least 28
             days prior to screening visit.

        MAJOR EXCLUSION CRITERIA:

          1. Severity of depressive episode had been rated as &quot;severe&quot; or &quot;severe with psychotic
             features.&quot;

          2. History of a suicide attempt or suicidal ideation.

          3. History of mania, manic episode or bipolar disease.

          4. Currently using a benzodiazepine or SSRI or more than 2 days of use within the 28 days
             preceding randomization.

          5. Use of prescription and non-prescription sedative drugs given for the purpose of sleep
             induction or to relieve jet lag

          6. Any abnormal pre-study laboratory values that require clinical intervention

          7. Prior failure to respond to escitalopram therapy for depression

          8. Current depressive episode requiring inpatient hospitalization.

          9. Shift work or requirement for a regular change in sleep schedule by at least six hours
             within the previous 28 days.

         10. History of drug addiction, alcoholism, or drug abuse.

         11. A positive urine drug screen for medication that would interfere with the assessment
             of the study medication.

         12. Known allergy to zolpidem, escitalopram or any of their excipients

         13. History of sleep apnea

         14. History of myasthenia gravis

         15. The presence of any untreated or uncompensated clinically significant renal,
             endocrine, gastrointestinal, hepatic, respiratory, cardiovascular, other neurologic,
             hematologic, oncologic, immunologic, cerebrovascular disease or malignancy.

         16. Pregnant or breastfeeding

         17. Subject is participating in another clinical trial, or has completed another clinical
             trial within 28 days prior to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phyllis Diener</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2006</study_first_submitted>
  <study_first_submitted_qc>February 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2006</study_first_posted>
  <last_update_submitted>July 25, 2008</last_update_submitted>
  <last_update_submitted_qc>July 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2008</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

